Medical-device and overseas expansion of retinal-scanning laser eyewear
First written in FY2021. 6 of 8 entries say "Advanced", first in FY2022. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025SoftenedAnnual report
「Sales ended in October 2024.」
Sales of the medical product RETISSA Medical ended in October 2024, narrowing the scope of the medical-device sales rollout. - FY2024AdvancedAnnual report
「The new consumer product ON HAND was launched in March 2023 and is currently sold through distributors. Sales also began in the United States in March 2024.」
Sales of the retinal-projection magnifying reader ON HAND began in the United States in March 2024, advancing the company's international expansion. - FY2024-Q3AdvancedAnnual report
「Sales increased from the same period of the previous year due to North American sales of RETISSA NEOVIEWER, a retinal-projection viewfinder, as well as higher sales of RETISSA MEOCHECK, an eye-health check tool, and the eye-health check service, among other factors.」
North American sales of RETISSA NEOVIEWER continued, while higher sales of MEOCHECK and the eye-health check service advanced expansion in international markets and the healthcare sector. - FY2024-Q2AdvancedAnnual report
「Sales increased from the same period of the previous year due to North American sales of RETISSA NEOVIEWER, a retinal-projection viewfinder, as well as higher sales of RETISSA MEOCHECK, an eye-health check tool, and the eye-health check service, among other factors.」
North American sales of RETISSA NEOVIEWER continued, while higher sales of MEOCHECK and the eye-health check service advanced expansion in international markets and the healthcare sector. - FY2024-Q1AdvancedAnnual report
「RETISSA NEOVIEWER, a retinal-projection viewfinder, began sales in North America, and sales increased from the same period of the previous year.」
The start of North American sales of the retinal-projection product RETISSA NEOVIEWER gave concrete shape to the international sales rollout. - FY2023AdvancedAnnual report
「In addition to developing and launching RETISSA MEOCHECK, which enables convenient eye-health checks, the company is developing fundus imaging equipment and new optometry equipment intended for medical-device applications through joint research with universities and other initiatives.」
In addition to medical devices and international expansion, the company's vision healthcare activities became more concrete through the launch of MEOCHECK and joint research on fundus imaging equipment and optometry equipment. - FY2022AdvancedAnnual report
「In Europe, the clinical trial began in August 2018 and ended in October 2019, and was completed in June 2021, including follow-up.」
The disclosure stated that, in addition to domestic approval and sales of medical laser eyewear, clinical trials and follow-up in Europe had been completed. - FY2021First statedAnnual report
「The company aims to obtain early coverage under medical insurance and other programs. It also seeks FDA approval in the United States and CE marking in Europe in order to establish a global medical-device sales business.」
Policy to expand the medical-device business through coverage under medical insurance after domestic approval and the start of sales, FDA approval in the United States, and CE marking in Europe.